The HIV glycan shield as a target for broadly neutralizing antibodies

FEBS Journal

Volumn 282, Issue 24, 2015, Pages 4679-4691

  Doores, Katie J ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

broadly neutralizing antibody; envelope trimer; glycosylation; HIV; vaccine

Indexed keywords

BROADLY NEUTRALIZING ANTIBODY; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; SIALIC ACID; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN; MANNAN; POLYSACCHARIDE;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MANNOSE PATCH; NONHUMAN; POTENTIAL N LINKED GLYCOSYLATION SITE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; REVIEW; TRIMERIZATION; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS GLYCAN SHIELD; VIRUS MORPHOLOGY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; GLYCOSYLATION; IMMUNOLOGY; METABOLISM; PROTEIN CONFORMATION; PROTEIN PROCESSING; PROTEIN STABILITY; SIMIAN IMMUNODEFICIENCY VIRUS; SURFACE PROPERTY;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GLYCOPROTEINS; GLYCOSYLATION; HIV; HUMANS; MANNANS; MODELS, MOLECULAR; POLYSACCHARIDES; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; SIMIAN IMMUNODEFICIENCY VIRUS; SURFACE PROPERTIES;

EID: 84959117772     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13530     Document Type: Review

References (86)

1. Fischer PB, Collin M, Karlsson GB, James W, Butters TD, Davis SJ, Gordon S, Dwek RA, &, Platt FM, (1995) The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J Virol 69, 5791-5797.
2. Dalziel M, Crispin M, Scanlan CN, Zitzmann N, &, Dwek RA, (2014) Emerging principles for the therapeutic exploitation of glycosylation. Science 343, 1235681.
3. Scanlan CN, Offer J, Zitzmann N, &, Dwek RA, (2007) Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446, 1038-1045.
4. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, et al,. (2003) Antibody neutralization and escape by HIV-1. Nature 422, 307-312.
5. Crispin M, &, Doores KJ, (2015) Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Curr Opin Virol 11, 63-69.
6. Burton DR, &, Mascola JR, (2015) Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 16, 571-576.
7. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P, et al,. (2012) Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 109, 18921-18925.
8. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, &, Burton DR, (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5, e1000433.
9. Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, &, Plotkin SA, (2013) Accelerating next-generation vaccine development for global disease prevention. Science 340, 1232910.
10. Ward AB, &, Wilson IA, (2015) Insights into the trimeric HIV-1 envelope glycoprotein structure. Trends Biochem Sci 40, 101-107.
11. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al,. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027.
12. Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD, et al,. (2012) PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol 86, 4394-4403.
13. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al,. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861.
14. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, et al,. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412.
15. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, et al,. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75, 10892-10905.
16. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang CH, et al,. (2014) Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40, 657-668.
17. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, et al,. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470.
18. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, et al,. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289.
19. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, &, Katinger H, (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70, 1100-1108.
20. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, &, Burton DR, (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 76, 7306-7321.
21. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, et al,. (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065-2071.
22. Doores KJ, Fulton Z, Huber M, Wilson IA, &, Burton DR, (2010) Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J Virol 84, 10690-10699.
23. Murin CD, Julien JP, Sok D, Stanfield RL, Khayat R, Cupo A, Moore JP, Burton DR, Wilson IA, &, Ward AB, (2014) Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy. J Virol 88, 10177-10188.
24. Doores KJ, Kong L, Krumm SA, Le KM, Sok D, Laserson U, Garces F, Poignard P, Wilson IA, &, Burton DR, (2015) Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. J Virol 89, 1105-1118.
25. Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, Ramos A, Diwanji DC, Pejchal R, Cupo A, et al,. (2013) Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 9, e1003342.
26. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, et al,. (2013) Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 20, 796-803.
27. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, et al,. (2012) Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 18, 1688-1692.
28. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, et al,. (2011) Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85, 9998-10009.
29. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, et al,. (2014) Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515, 138-142.
30. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, et al,. (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097-1103.
31. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, et al,. (2013) Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477-1483.
32. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, et al,. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343.
33. Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, Kulp DW, Julien JP, Menis S, Wickramasinghe L, et al,. (2014) Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med 6, 236ra263.
34. Geyer H, Holschbach C, Hunsmann G, &, Schneider J, (1988) Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. J Biol Chem 263, 11760-11767.
35. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, &, Gregory TJ, (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265, 10373-10382.
36. Mizuochi T, Spellman MW, Larkin M, Solomon J, Basa LJ, &, Feizi T, (1988) Structural characterization by chromatographic profiling of the oligosaccharides of human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells. Biomed Chromatogr 2, 260-270.
37. Mizuochi T, Spellman MW, Larkin M, Solomon J, Basa LJ, &, Feizi T, (1988) Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. Biochem J 254, 599-603.
38. Mizuochi T, Matthews TJ, Kato M, Hamako J, Titani K, Solomon J, &, Feizi T, (1990) Diversity of oligosaccharide structures on the envelope glycoprotein gp 120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. J Biol Chem 265, 8519-8524.
39. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, &, Detours V, (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 58, 19-42.
40. Pritchard LK, Spencer DI, Royle L, Bonomelli C, Seabright GE, Behrens AJ, Kulp DW, Menis S, Krumm SA, Dunlop DC, et al,. (2015) Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat Commun 6, 7479.
41. Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, Burton DR, Crispin M, &, Scanlan CN, (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6, e23521.
42. Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, Burton DR, Crispin M, &, Scanlan CN, (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci USA 107, 13800-13805.
43. Go EP, Herschhorn A, Gu C, Castillo-Menendez L, Zhang S, Mao Y, Chen H, Ding H, Wakefield JK, Hua D, et al,. (2015) Comparative analysis of the glycosylation profiles of membrane-anchored HIV-1 envelope glycoprotein trimers and soluble gp140. J Virol 89, 8245-8257.
44. Pritchard LK, Harvey DJ, Bonomelli C, Crispin M, &, Doores KJ, (2015) Cellular and protein-directed glycosylation of native cleaved HIV-1 envelope. J Virol 89, 8932-8944.
45. Pritchard LK, Vasiljevic S, Ozorowski G, Seabright GE, Cupo A, Ringe R, Kim HJ, Sanders RW, Doores KJ, Burton DR, et al,. (2015) Structural constraints determine the glycosylation of HIV-1 envelope trimers. Cell Rep 11, 1604-1613.
46. Bowden TA, Crispin M, Graham SC, Harvey DJ, Grimes JM, Jones EY, &, Stuart DI, (2009) Unusual molecular architecture of the machupo virus attachment glycoprotein. J Virol 83, 8259-8265.
47. Bowden TA, Crispin M, Harvey DJ, Aricescu AR, Grimes JM, Jones EY, &, Stuart DI, (2008) Crystal structure and carbohydrate analysis of Nipah virus attachment glycoprotein: a template for antiviral and vaccine design. J Virol 82, 11628-11636.
48. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, &, Dubuisson J, (2010) Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 84, 10159-10168.
49. Crispin M, Harvey DJ, Bitto D, Halldorsson S, Bonomelli C, Edgeworth M, Scrivens JH, Huiskonen JT, &, Bowden TA, (2014) Uukuniemi Phlebovirus assembly and secretion leave a functional imprint on the virion glycome. J Virol 88, 10244-10251.
50. Zhu X, Borchers C, Bienstock RJ, &, Tomer KB, (2000) Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39, 11194-11204.
51. Cutalo JM, Deterding LJ, &, Tomer KB, (2004) Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry. J Am Soc Mass Spectrom 15, 1545-1555.
52. Go EP, Irungu J, Zhang Y, Dalpathado DS, Liao HX, Sutherland LL, Alam SM, Haynes BF, &, Desaire H, (2008) Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J Proteome Res 7, 1660-1674.
53. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, &, Sodroski JG, (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705-711.
54. Go EP, Hewawasam G, Liao HX, Chen H, Ping LH, Anderson JA, Hua DC, Haynes BF, &, Desaire H, (2011) Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol 85, 8270-8284.
55. Go EP, Liao HX, Alam SM, Hua D, Haynes BF, &, Desaire H, (2013) Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J Proteome Res 12, 1223-1234.
56. Pritchard LK, Spencer DI, Royle L, Vasiljevic S, Krumm SA, Doores KJ, &, Crispin M, (2015) Glycan microheterogeneity at the PGT135 antibody recognition site on HIV-1 gp120 reveals a molecular mechanism for neutralization resistance. J Virol 89, 6952-6959.
57. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Pena AT, Korzun J, et al,. (2013) A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 9, e1003618.
58. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, et al,. (2013) Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342, 1484-1490.
59. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, et al,. (2014) Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514, 455-461.
60. Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, Korzun J, Derking R, van Montfort T, Julien JP, et al,. (2013) Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci USA 110, 18256-18261.
61. AlSalmi W, Mahalingam M, Ananthaswamy N, Hamlin C, Flores D, Gao G, &, Rao VB, (2015) A new approach to produce HIV-1 envelope trimers: both cleavage and proper glycosylation are essential to generate authentic trimers. J Biol Chem 290, 19780-19795.
62. Wang W, Nie J, Prochnow C, Truong C, Jia Z, Wang S, Chen XS, &, Wang Y, (2013) A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology 10, 14.
63. Francois KO, &, Balzarini J, (2011) The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry. J Biol Chem 286, 42900-42910.
64. Mathys L, Francois KO, Quandte M, Braakman I, &, Balzarini J, (2014) Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity. PLoS One 9, e101181.
65. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, et al,. (2006) Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80, 11776-11790.
66. Sagar M, Wu X, Lee S, &, Overbaugh J, (2006) Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 80, 9586-9598.
67. Pal R, Hoke GM, &, Sarngadharan MG, (1989) Role of oligosaccharides in the processing and maturation of envelope glycoproteins of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 86, 3384-3388.
68. Dewar RL, Vasudevachari MB, Natarajan V, &, Salzman NP, (1989) Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport. J Virol 63, 2452-2456.
69. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Pena AT, Cupo A, Julien JP, van Gils M, Lee PS, et al,. (2014) Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40, 669-680.
70. McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils M, Euler Z, Burger JA, Seaman MS, Sanders RW, et al,. (2015) Incomplete neutralization and deviation from sigmoidal neutralization curves for HIV broadly neutralizing monoclonal antibodies. PLoS Pathog 11, e1005110.
71. Doores KJ, &, Burton DR, (2010) Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84, 10510-10521.
72. Comelli EM, Sutton-Smith M, Yan Q, Amado M, Panico M, Gilmartin T, Whisenant T, Lanigan CM, Head SR, Goldberg D, et al,. (2006) Activation of murine CD4+ and CD8+ T lymphocytes leads to dramatic remodeling of N-linked glycans. J Immunol 177, 2431-2440.
73. Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD, Zwirner NW, Poirier F, Riley EM, Baum LG, et al,. (2007) Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 8, 825-834.
74. Crocker PR, Paulson JC, &, Varki A, (2007) Siglecs and their roles in the immune system. Nat Rev Immunol 7, 255-266.
75. Macauley MS, Crocker PR, &, Paulson JC, (2014) Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol 14, 653-666.
76. Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y, et al,. (2013) Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 20, 804-813.
77. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PN, Spencer DI, Seaman MS, et al,. (2012) Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA 109, E3268-E3277.
78. Garces F, Sok D, Kong L, McBride R, Kim HJ, Saye-Francisco KF, Julien JP, Hua Y, Cupo A, Moore JP, et al,. (2014) Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 159, 69-79.
79. Bernstein HB, Tucker SP, Hunter E, Schutzbach JS, &, Compans RW, (1994) Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. J Virol 68, 463-468.
80. Hansen JE, Clausen H, Hu SL, Nielsen JO, &, Olofsson S, (1992) An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus. Arch Virol 126, 11-20.
81. Stansell E, Panico M, Canis K, Pang PC, Bouche L, Binet D, O'Connor MJ, Chertova E, Bess J, Lifson JD, et al,. (2015) Gp120 on HIV-1 virions lacks O-linked carbohydrate. PLoS One 10, e0124784.
82. Yang W, Shah P, Toghi Eshghi S, Yang S, Sun S, Ao M, Rubin A, Jackson JB, &, Zhang H, (2014) Glycoform analysis of recombinant and human immunodeficiency virus envelope protein gp120 via higher energy collisional dissociation and spectral-aligning strategy. Anal Chem 86, 6959-6967.
83. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, et al,. (2015) HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349, aac4223.
84. Crooks ET, Tong T, Chakrabarti B, Narayan K, Georgiev IS, Menis S, Huang X, Kulp D, Osawa K, Muranaka J, et al,. (2015) Vaccine-elicited tier 2 HIV-1 neutralizing antibodies bind to quaternary epitopes involving glycan-deficient patches proximal to the CD4 binding site. PLoS Pathog 11, e1004932.
85. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, et al,. (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84, 1439-1452.
86. Scanlan CN, Ritchie GE, Baruah K, Crispin M, Harvey DJ, Singer BB, Lucka L, Wormald MR, Wentworth P Jr, Zitzmann N, et al,. (2007) Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. J Mol Biol 372, 16-22.